Aid maker Kenvue , even as the latter company faces thousands of lawsuits involving its painkiller Tylenol and talc-based baby powder, raising questions about the scope of the liabilities Kimberly-Clark might inherit.

D.E. Shaw, one of the Tylenol-maker’s largest shareholders, stood to lose over $200 million but is now expected to break even on its bet.

The announcement comes just weeks after President Trump publicly spread debunked claims that Tylenol consumption is linked to autism.

An AI collaboration boosted the company behind the largest U.S. cloud service on Monday, Nov. 3, 2025, while shares of the two companies involved in a consumer goods deal saw major moves.

Not long after President Trump made his statement, Kenvue and Johnson & Johnson got into another complicated legal mess when the Republican state of Texas sued them. The complaint says that the companies didn’t tell people about the possible risks of taking acetaminophen while pregnant.

A number of prominent hedge funds are likely applauding Monday’s news that Kimberly-Clark Corp. has agreed to acquire Kenvue for $48.7 billion, including debt. Shares of Kenvue, a Johnson & Johnson spin-off best known for its Tylenol,

Kenvue (KVUE) reported a net profit margin of 9.4%, up from 7.3% last year. One-year earnings growth reached 26.3%, and the company has a forecasted annual profit growth rate of 11.3%. The share price is $16.14, well below analyst fair value estimates of ...

Kimberly-Clark is buying Tylenol maker Kenvue in an approximately $48.7 billion cash-and-stock deal, creating a massive consumer health goods company